Biology
Pharmacogenomic Testing for CYP2D6 and Codeine Efficacy
Quick fact
About 7% of people are 'poor metabolizers' who cannot convert codeine into its active form, while up to 29% of some populations are 'ultrarapid metabolizers' who may produce life-threatening amounts of morphine.
Why this is interesting
Why does the same dose of codeine relieve pain in one person, but do nothing—or even cause dangerous side effects—in another? The answer lies in your DNA.
Read the full explanation
Understanding Pharmacogenomic Testing for CYP2D6 and Codeine Efficacy
Imagine codeine as a key that needs to be carved into the right shape before it can unlock your body's pain relief system. That carving is done by an enzyme called CYP2D6, predominantly in the liver. CYP2D6 is encoded by a gene that varies from person to person. Some people have multiple copies of the gene, producing more enzyme; others have mutations that result in a defective enzyme. These differences mean that after taking the same dose of codeine, the amount of morphine produced in the bloodstream can vary dramatically from person to person. Pharmacogenomic testing examines a person's CYP2D6 genetic variants to predict whether they will be a poor, intermediate, extensive, or ultrarapid metabolizer. This information helps doctors choose the right painkiller from the start, avoiding both inefficacy and toxicity.
A deeper explanation
Codeine itself is a prodrug—an inactive compound until it is metabolized. CYP2D6 catalyzes the O-demethylation of codeine to morphine, which then binds to opioid receptors to produce analgesia. The activity of CYP2D6 varies due to single nucleotide polymorphisms (SNPs), gene duplications, and deletions. Four main phenotypes arise: poor metabolizers (PM) have two non-functional alleles and produce negligible morphine, leading to no analgesic effect; intermediate metabolizers (IM) have reduced activity; extensive metabolizers (EM) have normal activity; and ultrarapid metabolizers (UM) carry multiple functional gene copies, converting codeine so rapidly that they may develop toxic morphine concentrations, causing severe respiratory depression or death. Pharmacogenomic testing analyzes these alleles before prescribing , placing patients into these categories. This allows clinicians to avoid codeine in PMs and UMs, choosing alternatives like non-opioid analgesics or other opioids that are not CYP2D6-dependent. By integrating this test into clinical practice, we shift from one-size-fits-all dosing to a precision medicine approach, improving efficacy and safety.